HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region

Garagiola, Elisabetta; Ferrario, Lucrezia; Croce, Davide; Menzaghi, Barbara; Quirino, Tiziana; Rizzardini, Giuliano; Foglia, Emanuela

doi:10.1016/j.dld.2016.06.028

Cited by 4 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, DAAs, for example, viral protease and NS5A inhibitors, can be reasonably regarded as the most promising drugs [10]. Drug pricing evolution in HCV and a budget impact analysis were described previously [11,12]. 75 Particularly, it was concluded that 'big pharma' use a value-based pricing model for HCV treatments.…”

Section: Aq4mentioning

confidence: 99%

Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

Ivanenkov

Aladinskiy

Bushkov

et al. 2017

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Non-structural 5A (NS5A) protein has achieved a considerable attention as an attractive target for the treatment of hepatitis C (HCV). A number of novel NS5A inhibitors have been reported to date. Several drugs having favorable ADME properties and mild side effects were launched into the pharmaceutical market. For instance, daclatasvir was launched in 2014, elbasvir is currently undergoing registration, ledipasvir was launched in 2014 as a fixed-dose combination with sofosbuvir (NS5B inhibitor). Areas covered: Thomson integrity database and SciFinder database were used as a valuable source to collect the patents on small-molecule NS5A inhibitors. All the structures were ranked by the date of priority. Patent holder and antiviral activity for each scaffold claimed were summarized and presented in a convenient manner. A particular focus was placed on the best-in-class bis-pyrrolidine-containing NS5A inhibitors. Expert opinion: Several first generation NS5A inhibitors have recently progressed into advanced clinical trials and showed superior efficacy in reducing viral load in infected subjects. Therapy schemes of using these agents in combination with other established antiviral drugs with complementary mechanisms of action can address the emergence of resistance and poor therapeutic outcome frequently attributed to antiviral drugs.

show abstract

Section: Aq4mentioning

confidence: 99%

Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

Ivanenkov

Aladinskiy

Bushkov

et al. 2017

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

show abstract

“…Nowadays, policy makers adopt Budget Impact Analysis (BIA) studies to estimate fiscal consequences of adopting new health technology or new medication (ISPOR, 2014). BIA estimates financial consequences of adopting a new health technology or intervention within a specific context (Garagiola, et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan

Massad¹,

Bakir²

2021

IJEFI

View full text Add to dashboard Cite

This paper assesses the impact of substituting clopidogrel with ticagelor to treat patients after an acute attack of Ischemic Heart Disease from the perspective of Jordanian MOH in its tenders, using Budget Impact Analysis (BIA). A multiple regression analysis used to estimate the elasticities associated of implementing the two treatments, and then Matlab used to compare the old and new treatments. The study recommends the gradually substitution of the new treatment using ticagelor because it achieves total cost savings of approximately 200,000 Jordanian dinars, and that the flexibility of the new treatment costs is less than in the case of the old treatment, which means that the increase in numbers of patients will lead to a lower increase in the total costs when using the new treatment.

show abstract

“…Despite their high efficacy, concerns have been raised about the costs associated with DAA therapy. With respect to the Italian scenario, different budget impact analyses have been published, however, considering only the drug cost19 or the complete treatment path 20. To date, no studies have investigated the actual cost sustained by the Italian National Health Service (NHS) during the first year of clinical use of second-generation DAAs.…”

Section: Introductionmentioning

confidence: 99%

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

Cenderello¹,

Fanizza²,

Marenco³

et al. 2017

CEOR

View full text Add to dashboard Cite

AimsDespite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria Region (Northern Italy).MethodsA retrospective analysis of the cost per care sustained for DAA treatment, relating to the period from January 1 to December 31, 2015 in five centers in Liguria was performed. All patients undergoing DAA-based treatments for hepatitis C virus (HCV) infection were enrolled. On-treatment costs included: HCV treatment, laboratory test, outpatient services, attended visits, drugs used for the management of adverse events (erythropoietin, albumin or red blood cell packs) and inpatient service admissions.ResultsIn total, 327 patients were enrolled. No difference in terms of sustained virologic response (SVR) rate among different treatments was reported. The majority (85.0%) of patients did not report any side effects and only 15 (4.6%) required hospital admission. Forty-two patients (12.8%) required high-cost drugs for the management of adverse events. The overall cost sustained was €14,744,433. DAA±ribavirin (RBV) accounted for the wide majority of this cost (98.9%; €14,585,123). Genotype (GT) 1, the most commonly treated GT, was associated with an average cost of €43,445 per patient. Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir±RBV with an average cost of €24,978 (RBV+) and €25,448 (RBV−) per patient was the most cost-effective. The average cost per SVR was €48,184. Once again, the ritonavir boosted paritaprevir/ombitasvir + dasabuvir regimen was associated with the lowest cost/SVR (€25,448/SVR [GT 1b] and similar results for other GTs).ConclusionAntiviral regimen is the major contributor to costs in the treatment of HCV infection. Appropriate regimen selection could result in a major cost saving, which can be reinvested to allow more patients to be treated.

show abstract

HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region

Abstract: Treating HCV-infected persons in the Lombardy Region with the new drugs would reduce healthcare expenditure on this specific disease, in each forecast implemented, thus reducing the economic burden of the pathology.

Cited by 4 publications

References 44 publications

Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015)

A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

Contact Info

Product

Resources

About